<DOC>
	<DOCNO>NCT01018615</DOCNO>
	<brief_summary>The purpose study determine safety , metabolism , antioxidant activity silymarin green tea extract change give combination patient chronic hepatitis C infection .</brief_summary>
	<brief_title>Safety , Metabolism , Antioxidant Activity Silymarin Green Tea Extract Patients With Chronic Hepatitis C</brief_title>
	<detailed_description>Silymarin green tea two widely use botanical product use patient chronic hepatitis C virus ( HCV ) infection . A major limitation prior clinical investigation may account lack efficacy use inadequate customary oral dose regimen . Ongoing Phase II study utilize high customary dos silymarin base potential disease modify effect result potent antioxidant property silymarin flavonolignans . Since patient often use one herbal product self-treat disease , use high customary dos silymarin may change silymarin 's potential herbal-herbal interaction . Pharmacokinetic interaction silymarin green tea catechin may change safety/tolerability profile , may increase antioxidant effect additive synergistic pharmacodynamic interaction . The objective double blind , active placebo control , randomize clinical trial characterize pharmacokinetics evaluate safety , tolerability , antioxidant effect herbal cocktail consist silymarin epigallocatechin gallate ( EGCG ) standardize green tea extract treatment-naïve patient chronic HCV infection . This investigation include four treatment arm enroll 15 subject per arm . Subjects randomize receive fix sequence either : 1 ) 280 mg silymarin follow coadministration 982.5 mg EGCG ; 2 ) 982.5 mg EGCG follow coadministration 280 mg silymarin ; 3 ) 196.5 mg EGCG follow coadministration 700 mg silymarin ; 4 ) 700 mg silymarin follow coadministration 196.5 mg EGCG . Each dose regimen administer p.o . every 12 hr 12 day . No treatment arm use high dos silymarin EGCG sequence . Depending treatment arm , pharmacokinetic study perform plasma concentration six major silymarin flavonolignans green tea catechin , EGCG end 12 day either silymarin green tea extract monotherapy ( Period 1 ) , 12 day silymarin green tea extract give combination ( Period 2 ) . For treatment arm , plasma 8F2α-isoprostane concentration , measure oxidative stress , also determine baseline , period , follow-up . The result investigation use identify dose silymarin green tea use together safely future efficacy trial patient different chronic liver disease .</detailed_description>
	<mesh_term>Hepatitis</mesh_term>
	<mesh_term>Hepatitis A</mesh_term>
	<mesh_term>Hepatitis C</mesh_term>
	<mesh_term>Hepatitis , Chronic</mesh_term>
	<mesh_term>Hepatitis C , Chronic</mesh_term>
	<mesh_term>Antioxidants</mesh_term>
	<mesh_term>Silymarin</mesh_term>
	<mesh_term>Epigallocatechin gallate</mesh_term>
	<criteria>Subjects eligible enrollment study meet follow criterion : Males female ; age least 18 year screen Negative urine pregnancy test ( woman childbearing potential ) document within 24hour period prior first dose silymarin . Females childbearing potential must use two reliable form effective contraception study ( drug followup ) Hepatitis C virus ( HCV ) patient Any HCV genotype Never treat receive less 50 % standard peginterferonbased therapy . No interferonbased therapy previous 6 month Serum HCV RNA quantifiable level detection assay , within 1 year screening . Before enter study , subject must agree consume alcohol 48 hour prior PK sample day study . Subjects follow eligible participation : Use milk thistle green tea preparation within 30 day Study Visit 1 ( Day 1 ) Use antioxidant vitamin E , vitamin C , glutathione , alphatocopherol , within 30 day Study Visit 1 ( Day 1 ) . A multivitamin standard dose allow . Use diet contain &gt; 6 serving per day , 46 serving per day &gt; 8 vegetable fruit list Appendix 2 . Allergy/sensitivity milk thistle , green tea preparation Inability tolerate milk product ( lactose intolerant ) Use interferonbased therapy last 6 month . Use warfarin , metronidazole chronic use acetaminophen great two gram per day Previous liver biopsy demonstrate presence cirrhosis previous liver biopsy demonstrate great equal 15 % steatosis evidence steatohepatitis Positive test antiHIV HBsAg within 3 year screen Positive urine drug screen drug abuse screen Alcohol consumption one drink equivalent ( &gt; 12 gram ) per day . Patients consume past must maintain level 12 gram less per day alcohol consumption least six month prior screen . History chronic liver disease , include metabolic disease , document appropriate test ( ) Women ongoing pregnancy breastfeeding , contemplate pregnancy Platelet count &lt; 130,000 cells/mm3 . Creatinine clearance ≤30cc/min currently dialysis . Creatinine clearance calculate accord CockcroftGault . Evidence alcohol drug abuse within 6 month prior screen Evidence decompensated liver disease define follow : serum albumin &lt; 3.2 g/dl , total bilirubin &gt; 1.5 mg/dl , PT/INR &gt; 1.3 time normal screening , history presence ascites encephalopathy , bleed esophageal varix History inflammatory bowel disease autoimmune hepatitis History solid organ bone marrow transplantation History thyroid disease poorly control prescribed medication Use oral steroid within 30 day prior screen Concurrent medication CYP3A4 inducer Inability unwillingness provide inform consent abide study protocol</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>November 2013</verification_date>
	<keyword>chronic hepatitis C</keyword>
	<keyword>silymarin</keyword>
	<keyword>green tea catechin</keyword>
	<keyword>green tea extract</keyword>
	<keyword>pharmacokinetics</keyword>
	<keyword>antioxidant activity</keyword>
</DOC>